Sophiris Bio Inc. (NASDAQ:SPHS) rose 5.7% on Thursday . The stock traded as high as $5.75 and last traded at $5.40, with a volume of 1,783,608 shares. The stock had previously closed at $5.11.

SPHS has been the subject of several recent analyst reports. Maxim Group restated a “buy” rating and set a $4.00 target price on shares of Sophiris Bio in a research note on Friday, June 10th. Echelon Wealth Partners restated a “buy” rating and set a $5.00 target price on shares of Sophiris Bio in a research note on Friday, June 10th.

The firm’s market capitalization is $112.41 million. The firm has a 50 day moving average of $2.68 and a 200-day moving average of $1.80.

Sophiris Bio (NASDAQ:SPHS) last posted its quarterly earnings results on Monday, May 16th. The biopharmaceutical company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.06. On average, equities analysts anticipate that Sophiris Bio Inc. will post ($0.73) EPS for the current fiscal year.

Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.